- What type of PhIIb data is worth $4 billion? Takeda’s Andy Plump has some thoughts on this.Terminal News
- “We’ll look back and say it was a good deal.” Takeda reveals early data for its $4 billion autoimmune disease pill.The Boston Globe
- Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, a Once-Daily Oral TYK2 Inhibitor, in People With Moderate-to-Severe Plaque Psoriasisbusiness thread
- Takeda’s $4 billion psoriasis pill helped clear skin in mid-term studyBloomberg
- Takeda rose to buy from BofA on growth prospects and debt repayment (NYSE:TAK)Looking for Alpha
- See full coverage on Google News